US CDC’s Adult RSV Vaccine Recommendations In Flux With Impending FDA Approvals

 
• By Bridget Silverman

Moderna touts enriched Phase II/III population and severe RSV data as CDC advisory committee re-evaluates shared clinical decision-making and prepares for expected June votes on Moderna’s mRNA-1345 and expanded adult use of GSK’s Arexvy.

older woman coughing with cartoon of her lungs drawn over her image.
CDC will likely update its recommendations on adult RSV vaccines in June. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers